🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesPost-prandial glucose control — 12 month update Page 2

Post-prandial glucose control — 12 month update

tammy_FL Tue, Nov 4, 2025 at 9:21 AM 10 replies 1,173 viewsPage 2 of 2
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
Nov 4, 2025 at 10:58 PM#6
tammy_FL said:
HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very…

Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:

BiomarkerAssociationEvidence Level
Baseline BMIHigher BMI → greater absolute weight lossStrong
Fasting insulinHigher insulin → better responseModerate
GLP1R gene variantsrs6923761 → variable responsePreliminary
Baseline hsCRPHigher CRP → greater CV benefitModerate
Early weight loss (4 wk)≥3% at 4 wks → strong predictor of ≥10% at 68 wksStrong

The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.

8 3maya_sedona, stefan_berlin, Dr.EM_Chicago and 5 others
Reply Quote Save Share Report
DadBodDave
Member
187
923
Nov 2024
Ohio
Nov 5, 2025 at 4:21 AM#7

A narrower follow-up, since the general answer is now clear:

Was that from a primary source or from a summary of one?

7 2JenMemphis, pat_auckland, Dr.GastroMayo and 4 others
Reply Quote Save Share Report
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Nov 5, 2025 at 9:44 AM#8
BethLabQueen said:
Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include: Biomarker Association…

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 5.5 (insulin resistant) → Current = 1.5 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

6 1FDA_TrackerJim, ricardo_MIA, BrianDallas92 and 3 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
tammy_FL
Member
234
890
Nov 2024
Tampa, FL
Nov 5, 2025 at 3:07 PM#9
BethLabQueen said:
Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include: Biomarker Association…

Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction than glucose or A1C.

My fasting insulin: 24 → 12 → 6 uIU/mL over 9 months. Target is <7. By the time your fasting glucose is elevated, your insulin has been elevated for YEARS trying to compensate.

Ask your doctor to include fasting insulin in your bloodwork panel. It's cheap (~$20) and incredibly informative.

5 0Dr.PainCLE, mike_mealprep, NicoleRaleigh and 2 others
Reply Quote Save Share Report
lori_vegas
Member
378
1,678
Aug 2024
Las Vegas, NV
Nov 6, 2025 at 5:00 PM#10
PeptideChemSF said:
Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking: HOMA-IR = (fasting…

My labs after 9 months on glycaemic control: A1C 5.4%, fasting glucose 89 mg/dL, fasting insulin 8 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 7.3% and fasting glucose was 114 mg/dL. The improvement has been dramatic and consistent.

49 22Dr.PathRoch, mona_PHX, andrew_nyc and 46 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register